Pepvise
Compound profile· Compounds

Melanotan 2, what the evidence shows

By The PepVise Editorial Team · Reviewed July 4, 2026 · 14 min read

Evidence Ledger for melanotan 2 (MT-2): a synthetic analog of alpha-MSH marketed as a tanning and libido agent, with no approval as a medicine and documented safety concerns ranging from nausea to changing moles.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature and regulators

MHRA/EMA safety warnings and PubMed search, 'melanotan II'

Melanotan 2 is unusual for this category because the most important literature is not about efficacy but about safety. UK and European regulators have explicitly warned against unlicensed melanotan injections, and case reports document changing moles, nausea, and other adverse effects. The combination of a regulator warning and case reports shows the real picture more honestly than any vendor page.

Reference reading

The texts we read alongside the papers.

  1. 01
    Regulator source

    MHRA consumer warning on unlicensed melanotan

    The UK medicines regulator, the MHRA, has repeatedly warned that melanotan tanning products are unlicensed and that their safety and quality have not been assessed. That warning is the most honest starting point: it establishes that this is not a regulated cosmetic but an unlicensed injectable substance, sold outside any medicines framework.

  2. 02
    Primary literature

    PubMed saved search, 'melanotan II'

    A PubMed search shows where the solid literature actually sits: in case reports and dermatology observations of adverse effects, especially the darkening and new appearance of pigmented lesions, and in the pharmacology of melanocortin receptors. It is the fastest way to separate the safety signals from the tanning marketing.

  3. 03
    Reference text

    Williams Textbook of Endocrinology (14th ed.)

    Melanotan 2 is a synthetic analog of alpha-MSH acting at melanocortin receptors, which influence pigmentation, appetite, and sexual function. Williams supplies the receptor biology needed to understand why one compound can produce effects as different as tanning and erection, and why that breadth is a flag for non-specific action rather than a benefit.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is melanotan 2 approved as a medicine?
No. Melanotan 2 has no approval from the FDA or EMA, and it is not a legal cosmetic. UK and other European regulators have explicitly warned that melanotan tanning injections are unlicensed. It is traded as a research chemical or an illegal tanning product labeled for non-human use.
Is melanotan 2 safe?
The documented safety concerns are substantial. Case reports describe nausea, flushing, blood-pressure changes, spontaneous erections, and, most importantly, new and darkening moles and changes in pigmented lesions that require dermatological review. Because the products are unlicensed, purity and dose are also unknown. Regulators advise against use.
Does melanotan 2 cause skin cancer?
There is no proof that melanotan 2 causes melanoma, but it is a serious concern rather than a settled question. It acts on the melanocortin pathway that governs pigment cells, and case reports document new and changing moles after use, which are the exact changes clinicians monitor as melanoma warning signs. At minimum it can obscure that surveillance, and the possibility of a more direct link is why the safety framing is cautious.
Is melanotan 2 the same as afamelanotide (Scenesse)?
No. Afamelanotide is a related melanocortin agonist that went through clinical development and is approved for a rare inherited light-sensitivity disorder, erythropoietic protoporphyria, and is given as a controlled implant under medical supervision. Melanotan 2 is a different, unlicensed compound sold for cosmetic tanning outside any medicines framework. Sharing a mechanism is not the same as sharing a safety and approval status.
Why does PepVise not give a melanotan 2 dose?
Because we describe the literature and do not recommend administration. With melanotan 2 that line is especially clear: there is no approved, dose-tested use, the products are unlicensed and uncertain in composition, and the safety signals are real. We explain how these substances are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.